Biologics are an increasingly significant part of the research pipeline, accounting for more than half of discovery-stage candidates and almost one-fifth of new applications for US Food and Drug Administration (FDA) approval. Although newly approved HIV treatment Atripla (efavirenz, emtricitabine, tenofovir), and human papilloma virus vaccine Gardasil are expected to garner >$1.5 billion in sales in 2007, almost all the major $1-billion-plus projections are for supplemental indications for mainstays like Avastin (bevacizumab) and Herceptin (trastuzumab).
Rights and permissions
About this article
Cite this article
Lawrence, S. Biotech blockbusters consolidate markets. Nat Biotechnol 24, 1466 (2006). https://doi.org/10.1038/nbt1206-1466
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1466
